Compare Novartis AG (NVS) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Plby Group Inc — how do they compare? Novartis AG trades at $142.97 (market cap $268.57B), while Plby Group Inc trades at $0.97 (market cap $118.21M). The key difference: Novartis AG is far larger — about 2272× Plby Group Inc's market cap, and Novartis AG pays a 3.31% dividend while Plby Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Plby Group Inc for 24 Days on average.
| NVS | PLBY | |
|---|---|---|
Market Cap | $268.57B | $118.21M |
Volume | 1,532,573 | 919,783 |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $2.71 |
52-Week Low | $121.80 | $0.99 |
Typical Hold Time | 82 Days | 24 Days |
Enterprise Value | $309.89B | $263.80M |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
PLBY trades at $1.02, down 1.92% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $12.67 million in 2025, though revenue grew to $120.93 million and the net loss narrowed significantly from prior years. Recent news highlights leadership appointments aimed at driving brand growth. The stock has a high P/E ratio of 49.34 but a reasonable P/S of 0.87, and analyst consensus is strongly bullish with 75% buy ratings.
The outlook is mixed: improving profitability trends and positive analyst sentiment offer potential upside, but high debt levels, negative shareholder equity, and bearish technicals pose significant risks. Investors should weigh the company's growth initiatives against its financial leverage and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
